GSK Wellbutrin Metabolite, Advair Successor In Phase II; NDAs In 2006-2008
GlaxoSmithKline expects to bring a Wellbutrin (bupropion) metabolite into Phase III studies for major depressive disorder during the second half of 2004
GlaxoSmithKline expects to bring a Wellbutrin (bupropion) metabolite into Phase III studies for major depressive disorder during the second half of 2004